Home  |  Contact

UniProtKB/Swiss-Prot Q9NQH7: Variant p.Gly453Cys

Xaa-Pro aminopeptidase 3
Variant information

Variant position:  453
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Cysteine (C) at position 453 (G453C, p.Gly453Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Nephronophthisis-like nephropathy 1 (NPHPL1) [MIM:613159]: A disorder with features of nephronophthisis, a cystic kidney disease leading to end-stage renal failure. Nephronophthisis is histologically characterized by modifications of the tubules with thickening of the basement membrane, interstitial fibrosis and, in the advanced stages, medullary cysts. Typical clinical manifestation are chronic renal failure, anemia, polyuria, polydipsia, isosthenuria, and growth retardation. Associations with extrarenal symptoms are frequent. In NPHPL1 patients, extrarenal symptoms include hypertension, essential tremor, sensorineural hearing loss and gout. Severely affected individuals can manifest a mitochondrial disorder with isolated complex I deficiency activity in muscle, seizures, mental retardation and hypertrophic dilated cardiomyopathy. {ECO:0000269|PubMed:20179356}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In NPHPL1.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  453
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  507
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.





Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 32 – 507 Xaa-Pro aminopeptidase 3
Metal binding 451 – 451 Manganese 1
Binding site 451 – 451 Substrate
Alternative sequence 279 – 507 Missing. In isoform 3.
Alternative sequence 289 – 507 Missing. In isoform 5.
Beta strand 453 – 456

Literature citations

Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy.
O'Toole J.F.; Liu Y.; Davis E.E.; Westlake C.J.; Attanasio M.; Otto E.A.; Seelow D.; Nurnberg G.; Becker C.; Nuutinen M.; Karppa M.; Ignatius J.; Uusimaa J.; Pakanen S.; Jaakkola E.; van den Heuvel L.P.; Fehrenbach H.; Wiggins R.; Goyal M.; Zhou W.; Wolf M.T.; Wise E.; Helou J.; Allen S.J.; Murga-Zamalloa C.A.; Ashraf S.; Chaki M.; Heeringa S.; Chernin G.; Hoskins B.E.; Chaib H.; Gleeson J.; Kusakabe T.; Suzuki T.; Isaac R.E.; Quarmby L.M.; Tennant B.; Fujioka H.; Tuominen H.; Hassinen I.; Lohi H.; van Houten J.L.; Rotig A.; Sayer J.A.; Rolinski B.; Freisinger P.; Madhavan S.M.; Herzer M.; Madignier F.; Prokisch H.; Nurnberg P.; Jackson P.K.; Khanna H.; Katsanis N.; Hildebrandt F.;
J. Clin. Invest. 120:791-802(2010)

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.